Log in | Register
Akshat Saxena BMedSc, Lourens Bester MBChB, BSc (Hons), FRANZCR, Terence C. Chua BSc (Med) (Hons), Francis C. Chu MBBS, FRACS, David L. Morris MD, PhD Gastrointestinal Oncology Volume 17, Issue 2 / February , 2009
View full article HTML | View full article PDF | Download Citation
There are no treatment options for unresectable intrahepatic cholangiocarcinoma (ICC) with proven efficacy. The objective of this study was to present data on the safety and efficacy of a novel treatment option, yttrium-90 (90Y) radioembolization for unresectable ICC.
Twenty-five patients underwent resin-based 90Y radioembolization for unresectable ICC between January 2004 and May 2009. Patients were assessed at 1 month and then at 3-month intervals after treatment. Radiologic response was evaluated with the Response Criteria in Solid Tumors (RECIST) criteria. Clinical and biochemical toxicities were prospectively recorded. Survival was calculated by the Kaplan-Meier method and potential prognostic variables were identified.
No patient was lost to follow-up. The median follow-up was 8.1 (range, 0.4–56) months and the median survival after 90Y radioembolization was 9.3 months. Two patients died within 1 month of treatment; the median follow-up for the remaining 23 was 8.9 (range, 1.5–56) months. Two factors were associated with an improved survival: peripheral tumor type (vs. infiltrative, P = .004) and Eastern Cooperative Oncology Group performance status of 0 (vs. 1 and 2, P < .001). On imaging follow-up of 23 patients, a partial response to treatment was observed in 6 patients (24%), stable disease in 11 patients (48%), and progressive disease in 5 patients (20%). The most common clinical toxicities were fatigue (64%) and self-limiting abdominal pain (40%). Two patients (8%) each developed grade III bilirubin and albumin toxicity. One patient (4%) developed grade III alkaline phosphatase toxicity.
90Y radioembolization may be a relatively safe and efficacious treatment for unresectable ICC. In the absence of other effective therapeutic options, this treatment warrants further investigation.
Go to Issue Contents
Add this article to your Personal Archive
The 2009 Impact Factor for Annals of Surgical Oncology has risen to 4.130. The journal is now ranked 6 of 166 journals publishing in Thomson Reuters' (formerly ISI) subject category "Surgery," making it the top ranked oncology journal in surgery.
HIGHLIGHTED VIDEO OF THE MONTH
Liver Resection with Portal Vein Thrombectomy for Hepatocellular Carcinoma With Vascular Invasion
Luca Aldrighetti MD, Carlo Pulitanò MD, Marco Catena MD, Marcella Arru MD, Eleonora Guzzetti MD, Jane Halliday MD, Gianfranco Ferla MD